Clinical Trials
866
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (720 trials with phase data)• Click on a phase to view related trials
SGLT2i in Kidney Stones
- Conditions
- Kidney Stones
- Interventions
- First Posted Date
- 2025-07-08
- Last Posted Date
- 2025-07-08
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 32
- Registration Number
- NCT07055282
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
Continuous Glucose Monitoring to Detect Postpartum Dysglycemia in Patients With Gestational Diabetes
- Conditions
- Gestational Diabetes
- First Posted Date
- 2025-06-24
- Last Posted Date
- 2025-06-24
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 50
- Registration Number
- NCT07034261
Mood Effects of Serotonin Agonists: Depression
- Conditions
- LSDMajor Depressive DisorderDepression
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-06-12
- Last Posted Date
- 2025-07-03
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 48
- Registration Number
- NCT07017478
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
Single Port Insufflation RCT
- Conditions
- Postoperative Pain Score
- First Posted Date
- 2025-05-25
- Last Posted Date
- 2025-05-25
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 70
- Registration Number
- NCT06990750
- Locations
- 🇺🇸
The University of Chicago, Chicago, Illinois, United States
Tibial IMN Vs. Tibial Micromotion IMN
- Conditions
- Tibial Fracture
- First Posted Date
- 2025-05-16
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 372
- Registration Number
- NCT06976801
- Prev
- 1
- 2
- 3
- 4
- 5
- 174
- Next
News
Sernova and Eledon Partner to Advance Type 1 Diabetes Bio-hybrid Organ Therapy with Novel Immunosuppression
Sernova Biotherapeutics and Eledon Pharmaceuticals announced a collaboration to evaluate tegoprubart, an anti-CD40L antibody, in Sernova's Phase 1/2 Cell Pouch Bio-hybrid Organ clinical trial for type 1 diabetes.
32 Biosciences Secures $6 Million Funding to Advance Gut Microbiome Diagnostic and Therapeutic Platform
32 Biosciences raised $6 million in funding to advance its AI-powered gut microbiome diagnostic platform and first-of-its-kind non-antibiotic antimicrobial therapy.
New Study Raises Safety Concerns About Fecal Microbiota Transplants
A new study published June 6, 2025, warns that fecal microbiota transplants may introduce microbes that hijack the host environment, potentially creating new health risks.
AB Science Secures Chinese Patent for Masitinib in COVID-19 Treatment Until 2041
AB Science has received a Chinese patent for its lead compound masitinib to treat COVID-19, providing intellectual property protection until April 2041.
ClostraBio Secures INVENT Illinois Funding, Appoints New CSO, and Prepares for Microbiome Therapeutic Launch
ClostraBio has secured new investment from the Illinois Innovation Venture Fund (INVENT) and NextGen Nutrition Investment Partners to advance its microbiome-focused therapeutics for gut health.
Weight Loss Drugs Wegovy and Zepbound Not Cost-Effective at Current Prices, Study Finds
Popular weight loss medications semaglutide (Wegovy) and tirzepatide (Zepbound) would need significant price reductions of 82% and 30% respectively to meet standard cost-effectiveness thresholds, according to new University of Chicago research.
Climate Change Extends Pollen Seasons, Prompting New Approaches to Allergy Management
Climate change has significantly extended pollen seasons across the United States, with western regions experiencing up to 20 additional freeze-free days, leading to prolonged allergy symptoms.
Radiation Oncology Pioneer Ralph Weichselbaum Named 2024 Giants of Cancer Care Inductee
Dr. Ralph R. Weichselbaum, chair of Radiation and Cellular Oncology at University of Chicago, has been named the 2024 Giants of Cancer Care inductee for his groundbreaking contributions to radiation oncology.
Dato-DXd Shows Promise in Previously Treated Advanced Non-Small Cell Lung Cancer
• Datopotamab deruxtecan (Dato-DXd) showed a numerical improvement in overall survival compared to docetaxel in previously treated advanced non-small cell lung cancer (NSCLC). • The TROPION-Lung01 trial highlighted a statistically significant improvement in progression-free survival in the nonsquamous NSCLC cohort treated with Dato-DXd. • A novel biomarker, TROP2 normalized membrane ratio (NMR), may predict outcomes to Dato-DXd, potentially refining patient selection. • Dato-DXd demonstrated a manageable safety profile with fewer dose reductions and treatment discontinuations compared to docetaxel.
Vertex's VX-880 Stem Cell Therapy Achieves Insulin Independence in Type 1 Diabetes Patients
Vertex Pharmaceuticals' VX-880 stem cell-derived islet cell therapy demonstrated remarkable efficacy in a Phase I/II trial, with all 12 full-dose patients achieving improved glycemic control and meeting ADA targets for HbA1c and time-in-range.